NANOLEK was given a market authorization by the Ministry of Health of the Republic of Belarus for the socially significant drug “Hunterase“ (Idursulfase beta) used in the treatment of the rare orphan disease Mucopolysaccharidosis type II. The drug is produced by Green Cross (Republic of Korea). At present, about 8 people in Belarus have been diagnosed with this disease.

The market authorization is issued for a period of 5 years.

Belarus became the third country where NANOLEK received a market authorization for this drug.